Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

This publication has 28 references indexed in Scilit:

• Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
  Blood, 2014
• Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
  The Lancet, 2013
• A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma
  PLOS ONE, 2013
• Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
  Journal of Clinical Oncology, 2012
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
  The Lancet Oncology, 2011
• Importance of Expert Central Review in the Diagnosis of Lymphoid Malignancies in a Regional Cancer Network
  Journal of Clinical Oncology, 2011
• Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
  Blood, 2009
• Stromal Gene Signatures in Large-B-Cell Lymphomas
  New England Journal of Medicine, 2008
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
  New England Journal of Medicine, 2002
• Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
  Journal of Clinical Oncology, 1999